Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Other Accumulated Expenses (2022 - 2025)

Historic Other Accumulated Expenses for Vivos Therapeutics (VVOS) over the last 4 years, with Q3 2025 value amounting to $987000.0.

  • Vivos Therapeutics' Other Accumulated Expenses rose 39597.99% to $987000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $987000.0, marking a year-over-year increase of 39597.99%. This contributed to the annual value of $273000.0 for FY2024, which is 3787.88% up from last year.
  • As of Q3 2025, Vivos Therapeutics' Other Accumulated Expenses stood at $987000.0, which was up 39597.99% from $1.0 million recorded in Q2 2025.
  • In the past 5 years, Vivos Therapeutics' Other Accumulated Expenses ranged from a high of $1.0 million in Q2 2025 and a low of $127000.0 during Q1 2023
  • Over the past 4 years, Vivos Therapeutics' median Other Accumulated Expenses value was $248500.0 (recorded in 2024), while the average stood at $363571.4.
  • As far as peak fluctuations go, Vivos Therapeutics' Other Accumulated Expenses tumbled by 5567.87% in 2023, and later surged by 57218.54% in 2025.
  • Quarter analysis of 4 years shows Vivos Therapeutics' Other Accumulated Expenses stood at $145000.0 in 2022, then skyrocketed by 36.55% to $198000.0 in 2023, then skyrocketed by 37.88% to $273000.0 in 2024, then soared by 261.54% to $987000.0 in 2025.
  • Its Other Accumulated Expenses stands at $987000.0 for Q3 2025, versus $1.0 million for Q2 2025 and $672000.0 for Q1 2025.